Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Brazilian researchers have performed the first-ever autopsy study to examine the precise causes of death in victims of the H1N1 swine flu.
LecTec Corporation announced today that it has issued the following open letter from Judd Berlin, the Chief Executive Officer of LecTec, to its shareholders regarding current developments at the Company:
The Advertising Specialty Institute® announced that hand sanitizers now rival pens as the most popular logoed items that companies are giving away to clients and employees.
The last large H1N1 influenza vaccination clinic for the 2009 flu season has been scheduled by the Macomb County Health Department. It is free of charge and will take place next Monday, Dec. 28, at Bethesda Christian Church in Sterling Heights from 10 a.m. to 3 p.m. Everyone over 6 months of age can receive the vaccine at this clinic.
The Department of Health will offer H1N1 flu vaccination clinics at 33 locations across Pennsylvania on Jan. 8 and 9, and anyone wishing to receive the vaccine is urged to make an appointment to attend.
Arrayit Corporation, a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics.
Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009.
UV Flu Technologies, Inc. wishes to advise it has recently acquired the assets of AmAirpure, Inc. in order to implement management's plans to move forward as an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality("IAQ") industry sector.
U.S. HealthWorks Medical Group, a leading operator of occupational health and urgent care centers in the nation, today announced that most of its 128 medical centers have new quantities of H1N1 vaccine available for walk-in patients – no appointments necessary.
CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine’ flu vaccine.
Duane Reade, the largest drug store chain in New York City, today announced that H1N1 vaccines are now available. As previously announced, Duane Reade pharmacies are providing New Yorkers with the H1N1 vaccine as part of the Company's commitment to servicing the health and wellness needs of the City's residents.
Select CVS/pharmacy locations and all MinuteClinic medical clinics throughout Arizona are now offering H1N1 vaccinations. H1N1 vaccine is now also available at select MinuteClinic locations in Illinois in the Chicago area and in Nevada in the Las Vegas area on demand seven days a week with no appointment necessary.
Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.
One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal.
TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.
Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ago may be coming to an end, according to a new report by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services.
Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.
MinuteClinic medical clinics in select CVS/pharmacy stores throughout Maryland, North Carolina and Tennessee are now offering H1N1 vaccinations on demand seven days a week with no appointment necessary.
There is no danger if your child received the H1N1 vaccine that was recalled by Sanofi Pasteur. That is the information being provided to anyone calling the NJ Poison Control Center's hotline, according to Bruce Ruck, Pharm.D., Director of Drug Information and Professional Education. The public should be reassured that this recall took place because specific lots were found to be slightly weaker than they should have been.
A Scientific American article examines recent efforts to tackle neglected tropical diseases (NTDs). The author writes "NTDs have plagued humankind for thousands of years. … What is new, however, is that donors, drugmakers, health ministries in low- and middle-income countries, the World Health Organization (WHO), and public-private partnerships are linking their efforts to combat the NTDs in a more coordinated and systematic way."
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.